LMF
CPIX icon

LMR Master Fund’s Cumberland Pharmaceuticals CPIX Stock Holding History

LMR Master Fund’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-23,416
Closed -$119K – 325
2013
Q2 		$119K Buy
+23,416
New +$117K 0.01% 403

Other funds holding CPIX

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KIM
Kestrel Investment Management San Mateo, California $167M AUM 20.81% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

LMR Master Fund's CPIX Position: Q3 2013 in Review

LMR Master Fund sold out of Cumberland Pharmaceuticals (CPIX) in Q3 2013, closing a stake of 23,416 shares — an estimated $119K sold.

LMR Master Fund first reported a position in CPIX in Q2 2013 and held it in 1 quarter. The position peaked at $119K in Q2 2013. 45 funds tracked by Wall St. Rank hold CPIX as of Q3 2013.

  • LMR Master Fund reported no remaining Cumberland Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • LMR Master Fund sold 23,416 Cumberland Pharmaceuticals shares in Q3 2013, an estimated $119K.
  • LMR Master Fund first reported a position in Cumberland Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • LMR Master Fund's Cumberland Pharmaceuticals position peaked at $119K in Q2 2013.
  • 45 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q3 2013.

Based on LMR Master Fund's 13F filing for Q3 2013, filed 14 Nov 2013.